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Abstract
 
In the chronic disabling disease multiple sclerosis (MS), migration of monocytes across the
blood-brain barrier is a crucial step in the formation of new lesions in the central nervous system
(CNS). Infiltrating monocyte-derived macrophages secrete inflammatory mediators such as oxygen
radicals, which contribute to axonal demyelination and damage, resulting in neurological deficits.
Flavonoids are compounds occurring naturally in food, which scavenge oxygen radicals and
have antiinflammatory properties. To investigate whether they might suppress clinical symptoms in
MS, we treated rats sensitized for acute and chronic experimental allergic encephalomyelitis, an
experimental model of MS, with flavonoids. We demonstrated that the flavonoid luteolin substan-
tially suppressed clinical symptoms and prevented relapse when administered either before or
after disease onset. Luteolin treatment resulted in reduced inflammation and axonal damage in
the CNS by preventing monocyte migration across the brain endothelium. Luteolin influenced
migration by modulating the activity of Rho GTPases, signal transducers involved in transendothe-
lial migration. Oral administration of luteolin also significantly reduced clinical symptoms.
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Introduction
 
Flavonoids are a large group of polyphenolic compounds
abundantly present in the human diet (1), first identified as
plant pigments, but now also recognized as very potent anti-
oxidants and immunomodulators (2). Depending on their
structure, flavonoids are divided in various subclasses like
flavonols, flavones, flavanones, and flavanols that differ in
their biological activity (3).
In multiple sclerosis (MS), reactive oxygen species
(ROS) play a crucial role in the migration process of leuko-
cytes across the blood-brain barrier. Treatment of endothelial
cells with superoxide is described to increase monocyte migra-
tion, whereas ROS scavengers impede this process (4). Besides
this, ROS are involved in MS pathology by inducing oxi-
dative damage to oligodendrocytes and neurons (5). The
interaction of leukocytes with endothelial cells activates
signal transduction pathways involving Rho GTPases like
RhoA and Rac1, leading to the cytoskeletal rearrange-
ments necessary for migration (6).
Previously, we described the flavone luteolin and especially
the flavonol quercetin as being potent antioxidants that inhibit
myelin phagocytosis by macrophages (7). Here, we report
that flavonoids have a beneficial effect in acute and chronic
experimental allergic encephalomyelitis (EAE). It was shown
that flavonoids influence monocyte migration across the
blood-brain barrier and modulate Rho GTPase activity.
 
Materials and Methods
 
EAE Induction and Flavonoid Treatment.
 
Acute EAE (acEAE)
was induced in Lewis rats (Hannover strain 230–250 g; Harlan) as
described previously (8). At day 0, rats were injected subcutane-
ously in the left footpad with an emulsion containing 20 
 
 
 
g guinea
pig myelin basic protein, 500 
 
 
 
g inactive 
 
Mycobacterium tuberculosis
 
type H37RA (Difco), and 50 
 
 
 
l complete Freund’s adjuvant
(Difco) supplemented with saline (0.9% NaCl) to reach a final vol-
ume of 100 
 
 
 
l. Chronic EAE (crEAE) was induced in adult male
Dark Agouti rats (220–260 g; Harlan) by two intradermal injec-
tions at the dorsal tail base with 75 
 
 
 
g rat recombinant myelin oli-
godendrocyte glycoprotein (MOG
 
1–125
 
) emulsified in incomplete
Freund’s adjuvant (Difco). A total volume of 100 
 
 
 
l was injected.
EAE induction was performed under isoflurane anesthesia. For
both sensitization protocols, control animals (
 
n 
 
  
 
3) received simi-
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lar emulsions without the encephalitogenic myelin basic protein or
myelin oligodendrocyte glycoprotein, respectively. Neurological
aberrations of EAE rats were scored daily and graded from 1 to 5:
0, no clinical signs; 0.5, loss of tonicity in distal half of tail; 1, flac-
cid tail; 1.5, unsteady gait; 2, partial hind limb paralysis; 2.5, com-
plete hind limb paralysis; 3, paralysis of the complete lower part of
the body up to the diaphragm; 4, paraplegia; and 5, death due to
EAE. Clinical scores were derived from 8–13 animals per group.
Quercetin and luteolin (purity 
 
  
 
97% HPLC grade; Kaden
Biochemicals) were dissolved in 1 N NaOH. The pH was read-
justed to 7.2 with 1 N HCl after which the solutions were further
diluted in saline and distilled water. Flavonoids were administered
at 50 mg/kg daily i.p. from day 6 to 18 during acEAE and from
day 6 to 24 or day 15 to 24 during crEAE. When indicated, lu-
teolin was administered orally (intragastrically) at 100 mg/kg
from day 3 to 24. All experimental procedures were approved by
the Experimental Animal Committee of the VUMC.
 
Immunohistochemistry.
 
Rats were killed at various time points
after acEAE and crEAE induction. After perfusion of the animals
with 4% formalin, brains and spinal cords were dissected, post-
fixed in 4% formalin for 1 wk, and embedded in paraffin. 8-
 
 
 
m
thick sections were dewaxed, endogenous peroxidase activity was
blocked with 1% H
 
2
 
O
 
2 
 
in methanol, and then sections were mi-
crowaved for 10 min in 0.1 M citric acid, pH 6. Sections were
incubated with the mAb ED1 (Serotec) raised against the mac-
rophage-specific CD68 antigen, the mAb W3/13 (Serotec) raised
against the pan–T cell marker CD43, or the mAb 348 (Chemi-
con) raised against amyloid precursor protein (APP). Binding of
primary antibodies was revealed by avidin-biotin-peroxidase as
described previously (9), with reagents supplied by Vector Labo-
ratories. Cellular infiltrates and APP
 
  
 
dots were quantified in 20–
30 pictures per rat, taken with a digital camera at 10
 
  
 
objective
throughout the spinal cord, using the digital image analysis pro-
gram AnalySIS (Soft Imaging System GmbH).
 
Monocyte Migration.
 
The migratory capacity of monocytes
over a brain endothelial cell monolayer was assayed by time-lapse
video microscopy, as described previously (4). In brief, brain en-
dothelial monolayers were established using the well-character-
ized, immortalized Lewis rat brain endothelial cell line GP8/3 (4,
10). 5 
 
  
 
10
 
5
 
/ml monocytes were added to the endothelial cell
monolayers and the number of migrated monocytes was assessed
after 4 h. The migration assay was conducted with or without the
presence of 50 
 
 
 
M luteolin. The effect of luteolin on monocyte
migration was determined using the rat NR8383 monocytic cell
line, which resembles primary monocytes in its migratory behav-
ior (11) and V14Rho-NR8383 cells, which overexpress constitu-
tively active RhoA (12). The migration capacity of monocytes
derived from control rats and vehicle- or luteolin-treated crEAE
animals was also established. Peripheral blood monocytes were
purified as described previously (10). Mononuclear cells (PBMCs)
were obtained from a concentrated cell pool obtained after perfu-
sion of rats and centrifugation on a Ficoll-Paque gradient. Subse-
quently, B and T cells were removed using immunomagnetic
separation and granulocytes and remaining blood cells were re-
moved using FACS sorting on their size and granularity. 20–30 
 
 
 
10
 
6 
 
monocytes were isolated from one rat. 5 
 
  
 
10
 
5
 
/ml monocytes
and 50% serum of the same animals were added to brain endothe-
lial cell monolayers to determine monocytic migration behavior.
 
RhoA and Rac1 Activity Assays.
 
RhoA and Rac1 activity as-
says were performed as described previously (4, 13, 14). RhoA and
Rac1 activities were determined in 5 
 
  
 
10
 
6 
 
or 20 
 
  
 
10
 
6 
 
NR8383
cells, respectively, after treatment with 50 
 
 
 
M luteolin for 1 h.
Cells were washed in ice-cold PBS and lysed. Cleared lysates were
incubated with either bacterially produced GST-RBD (Rhotekin)
bound to glutathione-agarose beads purified from bacterial lysates
as described previously (13), or PAK-CRIB-bio (provided by J.G.
Collard, The Netherlands Cancer Institute, Amsterdam, Nether-
lands) purified with streptavidin-agarose beads. Beads were washed
Figure 1. The flavonoids luteolin
and quercetin suppress acEAE and
prevent monocyte infiltration into the
CNS. (A and B) Animals sensitized for
acEAE (n     11) were injected i.p.
with either quercetin (A, n   11) or
luteolin (B, n   11) from day 6. Both
quercetin (A,  ) and luteolin (B,  )
treatment delayed and significantly re-
duced clinical symptoms of acEAE
compared with vehicle-treated controls (A and B,  ). (C) Immunohistochemical analysis of
ED1  macrophages in the spinal cords of vehicle-, quercetin-, and luteolin-treated animals at
day 14. Original magnification of 100, counterstained with hematoxylin. (D) Quantification of
ED1  macrophages in three representative rats from each treatment group. Data represent
means   SEM. *, P   0.05. Student’s t test. 
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three times with lysis buffer, and bound proteins were eluted in
SDS sample buffer and analyzed by Western blotting using anti-
RhoA (Santa Cruz Biotechnology, Inc.) or anti-Rac1 (clone 23A8;
Upstate Biotechnology) mAbs. Luteolin treatment did not affect
total RhoA or Rac1 content of the cells as assessed by Western
blotting of total lysates (not depicted).
 
Statistics.
 
Data were analyzed statistically by means of analysis of
variance, Student’s 
 
t
 
 test, and Spearman’s rank correlation coefficient.
 
Results and Discussion
 
Flavonoids Suppress acEAE by Preventing Leukocyte Infiltra-
tion.
 
The potential beneficial effect of flavonoids in MS
was determined in the acEAE model. acEAE animals were
injected daily i.p. with either one of the flavonoids (50 mg/
kg quercetin or luteolin) from day 6 after induction. All ve-
hicle-treated acEAE animals developed neurological symp-
toms from day 10, with a maximum score at day 14, and
were recovered by day 18 after disease induction (Fig. 1, A
and B). In all rats that had been treated with quercetin, dis-
ease was initiated, although its onset was significantly de-
layed by at least 1 d (P 
 
  
 
0.05), and clinical symptoms were
slightly though significantly reduced (P 
 
  
 
0.05; Fig. 1 A).
Treatment with luteolin substantially suppressed the devel-
opment of acEAE (P 
 
  
 
0.01). Disease incidence was ob-
served in only 36% of these animals. Within this treatment
group, the mean maximum disease score was 0.4 compared
with 2.3 for vehicle-treated animals, and disease onset was
delayed with a mean of 6 d (P 
 
  
 
0.01; Fig. 1 B). Upon ter-
mination of luteolin administration at day 17, no increase
in the clinical symptoms of diseased animals occurred, and
animals were completely recovered by day 21. Histological
examination at the peak of regular disease progression (day
14) revealed reduced numbers of infiltrated T cells (not de-
picted) and macrophages in quercetin- and luteolin-treated
animals. Macrophage numbers were reduced by 17 and
88% (P 
 
  
 
0.05), respectively, compared with vehicle-
treated animals (Fig. 1, C and D). These data demonstrate
that luteolin significantly reduces the development and se-
verity of acEAE, and prevents leukocyte infiltration into
the central nervous system (CNS). Luteolin was found to
be more potent than quercetin, indicating the importance
of the lack of a hydroxyl group at the C-3 position (7), the
only structural difference between the two flavonoids.
 
Luteolin Blocks Monocyte Migration across Brain Endothelial
Cells by Influencing Rho GTPase Activity.
 
The effect of lu-
teolin in a well-established in vitro migration model was
assessed to further investigate its mechanism in inhibiting
cellular migration across the blood-brain barrier. ROS are
required for the diapedesis of monocytes across brain en-
dothelium, and the migration process can be inhibited by
antioxidants (4). As anticipated, luteolin impaired migra-
tion of the rat monocytic cell line NR8383 across a brain
endothelial cell monolayer by 71% as determined by video
time-lapse microscopy (P 
 
  
 
0.01; Fig. 2 A). Adhesion of
NR8383 cells to brain endothelial cells as well as the viabil-
ity of both cell types, assessed as described previously (4, 7),
remained unaffected (not depicted). However, we observed
a clear reduction in monocyte motility and the formation
of monocytic membrane protrusions when treated with lu-
teolin. During luteolin treatment, monocytes showed less
membrane protrusions as analyzed by the video images of
the migration experiments (Fig. 2 B). Upon quantification,
49% of luteolin-treated monocytes revealed no clear mem-
brane protrusions compared with 100% of untreated cells,
indicating that the flavone may affect cytoskeletal regula-
tory components such as the family of the Rho GTPases.
Activation of RhoA is particularly essential for migration
and the completion of diapedesis of monocytes (12, 15).
Therefore, the effect of luteolin on RhoA activity was as-
sessed. Incubation of NR8383 cells with 50 
 
 
 
M luteolin
for 1 h indeed inhibited RhoA GTP loading by 64% (P 
 
 
 
0.01; Fig. 2 C). Overnight incubation of monocytes with
10 
 
 
 
M luteolin also decreased levels of active RhoA by
60%.
To exclude regulation of other signaling pathways by lu-
teolin, we determined the influence of luteolin on migra-
tion of monocytes that express constitutively active RhoA
(12). Luteolin did not inhibit the migration capacity of
these monocytes, indicating that constitutively active RhoA
in monocytes overcomes luteolin-induced decrease in
transmigration (Fig. 2 D). As Rac1, a close family member
of RhoA and part of the NADPH–oxidase complex, is de-
scribed to down-regulate RhoA (16), we also determined
Rac1 GTP loading upon luteolin treatment. Rac1 activity
was increased by 144% upon luteolin treatment for 1 h
(P 
 
  
 
0.05; Fig. 2 E) and by 50% after 4 h, suggesting that
luteolin may directly regulate RhoA activity via Rac1.
Conversely, Rac1 is reported to inhibit RhoA by activa-
tion of the NADPH–oxidase complex (17), which is not in
line with our earlier observations that luteolin is an effec-
tive scavenger of ROS (7). Therefore, we assume that
other signaling pathways must be involved in the effects
mediated by luteolin. Our data are consistent with previous
reports that have demonstrated that Rho GTPase inhibitors
are protective in acEAE through prevention of leukocyte
infiltration into the CNS (18). Interestingly, the family of
the cholesterol-lowering drugs, for instance lovastatin, is
also beneficial in EAE and is reported to inhibit the activa-
tion of RhoA (19–20). Thus, observed diminished mono-
cyte migration and infiltration into the CNS of EAE ani-
mals by luteolin treatment might be mediated by inhibition
of RhoA activity.
 
Luteolin Is Protective in crEAE When Administered before and
after Disease Onset and by Oral Treatment.
 
The therapeutic
potential of luteolin was assessed in a chronic relapsing-
remitting model for MS. crEAE rats were treated daily
with 50 mg/kg luteolin i.p. from day 6 after induction. Ve-
hicle-treated crEAE animals developed clinical symptoms
at day 7, with a peak at day 12. These animals then tempo-
rarily recovered around day 16, whereafter a second clinical
episode developed from which the animals did not recover
(Fig. 3, A and B). Luteolin administration greatly amelio-
rated clinical crEAE symptoms as previously observed with
the acEAE model (Fig. 1 B). Administration of luteolin be- 
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fore disease onset, from day 6, almost completely abolished
the first clinical episode (P 
 
  
 
0.01, no disease symptoms in
91% of animals). In addition, the second, more chronic
phase was also significantly suppressed (P 
 
 
 
 0.05, 69% re-
duction of clinical symptoms; Fig. 3 A). Ending luteolin
treatment at day 24 led to an incline in clinical symptoms
that became as severe as those of vehicle-treated crEAE an-
imals at day 28 (
 
n 
 
  
 
5; not depicted).
The effectiveness of luteolin in diminishing clinical symp-
toms in crEAE rats after its onset was evaluated by treat-
ing crEAE animals with 50 mg/kg luteolin after the first
clinical episode, from day 15 onwards. Clinical symptoms
were completely abolished within 5 d of luteolin adminis-
tration, whereas vehicle-treated crEAE animals suffered a
severe relapse (Fig. 3 B). Upon ending treatment at day 24,
luteolin-treated rats remained free of clinical symptoms un-
til day 27, after which disease developed and progressed to
become as severe as that in control crEAE animals (
 
n 
 
  
 
5;
not depicted). This indicates that the continuous presence
of luteolin will be required to maintain suppression of
crEAE.
As shown for the acEAE model (Fig. 1, C and D), luteo-
lin treatment reduced the infiltration of leukocytes into the
CNS in crEAE when treatment was started both at day 6
and at day 15. Significantly reduced numbers of macro-
phages (P 
 
  
 
0.05; Fig. 3 C) and T cells (P 
 
 
 
 0.05; not de-
picted) were found in the spinal cords of luteolin-treated
rats. Axonal damage, as indicated by an accumulation of
APP, was also reduced (P 
 
  
 
0.05), and this correlated with
the number of infiltrated macrophages (P 
 
 
 
 0.01; Fig. 3 D).
As luteolin directly influences monocyte migration in
vitro (Fig. 2 A), we evaluated whether monocytes derived
from luteolin-treated crEAE rats were affected in their mi-
gratory behavior. Blood monocytes were isolated from lu-
teolin- and vehicle-treated animals and tested in vitro for
their capacity to migrate across a brain endothelial cell
layer. Monocytes derived from luteolin-treated animals in-
deed showed reduced migration, at both phases of disease
(Fig. 3 E; P 
 
 
 
 0.05), revealing that inherent monocyte mi-
gratory behavior is affected by luteolin in vivo.
Because flavonoids are dietary compounds, their effec-
tiveness on disease severity after oral administration was
Figure 2. Luteolin reduces monocyte migra-
tion across brain endothelial cells by modulating
Rho GTPase signaling. (A) Luteolin inhibited
migration of the monocytic cell line NR8383
across a brain endothelial cell layer. Migration
of untreated monocytes was set at 100%. (B) Dur-
ing luteolin treatment, monocytes showed less
membrane protrusions as compared with control
cells as analyzed by video microscopy. (C) Luteo-
lin treatment (50  M) for 1 h inhibited RhoA
activity in NR8383 cells. The amount of RhoA
in untreated cells was set at 100%. Lanes are
derived from different parts of the same gel.
(D) RhoV14 monocytes (NR8383 monocytes
overexpressing constitutively active RhoA) had
an increased migration capacity compared with
control monocytes. 50  M Luteolin did not
significantly affect migration of RhoV14
monocytes. (E) In contrast to RhoA, luteolin
treatment for 1 h promoted Rac1 activity in
NR8383 cells. The amount of Rac1 in un-
treated cells was set at 100%. Lanes are derived
from different parts of the same gel. Data repre-
sent at least three independent experiments and
are expressed as the means   SEM. *, P   0.05.
Student’s t test. 
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tested. crEAE animals were treated orally from day 3 after
induction with 100 mg/kg luteolin. This treatment also re-
sulted in a delayed onset (P 
 
  
 
0.05; 4 d) of both disease
phases and significantly inhibited the first phase (P 
 
  
 
0.01;
Fig. 3 F) in a manner similar to observed i.p. treatment
(Fig. 3 A). However, at day 24, luteolin-treated animals
started to develop clinical scores similar to control crEAE
animals (not depicted).
Flavonoids are poorly absorbed from the digestive tract,
but their metabolites might be functionally active (21). Af-
ter oral administration of luteolin in rodents, serum con-
centrations of unmodified luteolin and its conjugates were
detected (22), which were functionally active in reducing
proinflammatory cytokine production (23) and present at a
similar concentration range to that used in our in vitro as-
says. Luteolin is present in large quantities in vegetables and
herbs like artichokes, celery, and parsley. Additionally,
other flavonoids are abundantly present in our diet in fruits,
vegetables, herbs, seeds, and plant-derived products like red
wine and tea (USDA database: http://www.nal.usda.gov/
fnic/foodcomp). The total dietary flavonoid intake is esti-
mated to be several hundreds of milligrams per day (21).
Therefore, a luteolin- or flavonoid-enriched diet might be
sufficient to reach intake levels that are beneficial in MS.
Luteolin might be especially beneficial together with struc-
turally similar flavonoids like apigenin and other possibly
protective dietary compounds like vitamin D, lipoic acid,
and curcumin (24–26). Taken together, these data stress the
potential impact of nutritional components on the progres-
sion of MS.
 
We thank H. Honing (University Medical Center, Utrecht, Neth-
erlands) and J.G. Collard (The Netherlands Cancer Institute, Am-
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Figure 3. Luteolin abolishes clini-
cal symptoms in crEAE. (A) crEAE
animals treated i.p. with luteolin
(n   13,  ) from day 6 show re-
duced clinical signs compared with
vehicle-treated crEAE controls (n  
13,  ). (B) Treatment of crEAE animals
with 50 mg/kg luteolin (n   10,  )
i.p. after disease onset (from day 15)
rapidly abolished clinical symptoms
compared with vehicle-treated ani-
mals (n   13,  ) that developed a
severe relapse. (C) Luteolin-treated
animals showed reduced numbers of
ED1   macrophages in their spinal
cords. Macrophage infiltrates were
quantified in three representative
rats from each treatment group. (D)
Numbers of macrophages present in
the spinal cords of vehicle- and luteo-
lin-treated rats correlated with the
presence of axonal damage as detected
by APP accumulation and assessed by
the Spearman’s rank correlation co-
efficient (P   0.01). (E) Peripheral
blood monocytes isolated at days 12
and 22 from crEAE animals treated
with luteolin from days 6 and 15, re-
spectively, were impaired in their
capacity to migrate across brain en-
dothelial cells in vitro compared
with monocytes derived from crEAE
control animals. Experiments were
conducted in the presence of 50%
serum derived from the same ani-
mals (A and B). (F) Oral treatment
with luteolin (n   10,  ) from day
3 onwards delayed disease onset and
reduced clinical symptoms compared
with control crEAE animals ( ).
Data are expressed as the means  
SEM. *, P   0.05. Student’s t test. 
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